Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects — COG0108  

Alzheimer Disease Clinical Trial

Official title: A Phase 1, Open-Label Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of [14C] CT1812 in Healthy Adult Male Subjects

Status Completed

Clinical Trial Summary

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812

Clinical Trial Description

Open-label, single-dose study to assess the absorption, metabolism, excretion and mass balance of [C14] CT1812 in 8 healthy male subjects

Subjects will be screened 28-days prior to dosing to determine eligibility.

Eligible subjects will be admitted to the clinical research unit (CRU) on Day -1. On Day 1, subjects will receive a single dose of CT1812 with a microtracer dose of [14C] CT1812. Whole blood, plasma, urine and fecal samples will be collection during the confinement period. Safety will be monitored throughout the study by repeated clinical and laboratory evaluations.

Subjects will be and discharged from the CRU following completion of procedures 168 hours post dose (Day 8) ;

Related Conditions & MeSH terms

• Alzheimer Disease

• NCT number: NCT05225389
• Study type: Interventional
• Source: Cognition Therapeutics
• Status: Completed
• Phase: Phase 1
• Start date: December 31, 2021
• Completion date: January 24, 2022